Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:1
  • preuzimanja u poslednjih 30 dana:0
članak: 9 od 32  
Back povratak na rezultate
Acta medica Medianae
2016, vol. 55, br. 3, str. 38-43
jezik rada: engleski
vrsta rada: originalan članak
doi:10.5633/amm.2016.0306
Creative Commons License 4.0
Alkoholna ciroza jetre i poremećaj aterogenih faktora u plazmi
aMedicinski fakultet, Niš + Klinika za gastroenterologiju i hepatologiju, Klinički centar, Niš
bInstitut za kardiovaskularne bolesti, Sremska Kamenica
cDom zdravlja, Medveđa

e-adresa: bovail@gmail.com

Sažetak

Alkohol se metaboliše alkoholnom dehidrogenazom do acetaldehida, pa aldehid dehidrogenazom uz acetil koenzima-A do acetata. Tako nastali vodonik prihvata nikotinamid adenin dinukleotid, te se akumuliraju masne kiseline u jetri. Ciroza jetre nastaje unosom alkohola od 80 g/dan za muškarce, a 20 g/dan za žene. Cilj studije bio je da se utvrdi profil aterogenih faktora plazme bolesnika sa alkoholnom cirozom jetre u odnosu na bolesnike sa cirozom jetre uzrokovanom HCV infekcijom i odredi njihov dijagnostički značaj. Studija upoređuje ukupni holesterol (TC), trigliceride (Tg), visoke-gustine lipoprotein holesterol (HDL-C), niske-gustine lipoprotein holesterol (LDL-C) i apolipoproteine (ApoA1 i ApoB) u plazmi bolesnika sa alkoholnom cirozom jetre i bolesnika sa cirozom jetre i HCV infekcijom. Izračunavan je i upoređivan odnos TC/HDL-C i ApoB/ApoA1 i LDL-C/HDL-C u obe grupe bolesnika. Studija uključuje 37 bolesnika sa alkoholnom cirozom jetre, prosečne starosti 52,65 godina (SD-6,73), koji su konzumirali alkoholne napitke prosečno 8,67 godine (SD-1,96) i 35 bolesnika sa cirozom jetre i HCV infekciom. Žena je bilo 21,62%, a 78,38% muškaraca sa alkoholnom cirozom jetre; 34,29% žena i 65,71% muškaraca sa cirozom jetre izazvanom HCV-om. Prosečne vrednosti Tg su 11,91 mmol/l (SD-2,51), TC 14,63 (SD-2,62), LDL-C 8,77 mmol/l (SD-2,19), HDL-C 0,41 mmol/l (SD-0,09), apolipoprotein-B 4,01 g/l (SD-0,18), apolipo-protein-A1 0,51 g/l (SD-0,08) kod alkoholne ciroze jetre, a u HCV cirozi Tg su prosečne vrednosti 8,62 mmol/l (SD-2,31), TC 9,67 (SD-2,39), LDL-C 6,12 mmol/l (SD- 1,78), HDL-C 0,76 mmol/l (SD-0,09), apolipoprotein-B 2,38 g/l (SD-0,16), i apolipoprotein-A1 0,98 g/l (SD-0,05). Odnos apolipoprotein-B/apolipoprotein-A1 može poslužiti kao dija-gnostički marker prisustva alkoholne ciroze i bolji je pokazatelj aterogenog rizika.

Ključne reči

Reference

*** (2006) Alcohol use and alcohol use disorders in the United States: Main findings from the 2001-2002 national epidemiologic survey on alcohol use and related conditions (NESARC). Bethesda: National Institutes of Health
*** (2005) Helping patients who drink too much: A clinicians guide. Bethesda: U.S. Department of Health and Human Services-National Institute of Health
Aalto, M. (2005) Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol and Alcoholism, 40(6): 520-523
Aertgeerts, B., Buntinx, F., Kester, A. (2004) The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: a diagnostic meta-analysis. Journal of clinical epidemiology, 57(1): 30-9
Alte, D., Luedemann, J., Rose, H., John, U. (2004) Laboratory Markers Carbohydrate-Deficient Transferrin, γ-Glutamyltransferase, and Mean Corpuscular Volume Are Not Useful as Screening Tools for High-Risk Drinking in the General Population: Results From the Study of Health in Pomerania (SHIP). Alcoholism: Clinical and Experimental Research, 28(6): 931-940
Anttila, P., Järvi, K., Latvala, J., Romppanen, J., Punnonen, K., Niemelä, O. (2005) Biomarkers of alcohol consumption in patients classified according to the degree of liver disease severity. Scandinavian journal of clinical and laboratory investigation, 65(2): 141-51
Barrio, E., Tomé, S., Rodríguez, I., Gude, F., Sánchez-Leira, J., Pérez-Becerra, E., González-Quintela, A. (2004) Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcoholism, clinical and experimental research, 28(1): 131-6
Chen, J. (2003) Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol and Alcoholism, 38(6): 574-582
Daniel, J.R., Helen, H.H. (2012) Disorders of lipoproteinmetabolism. u: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, [ur.] Harrisonsprinciples of internal medicine, New York: McGraw-Hill Medical Publisher Division, p. 3145-61; 18th ed
Hannuksela, M.L., Liisanantti, M.K., Nissinen, A.E.T., Savolainen, M.J. (2007) Biochemical markers of alcoholism. Clinical chemistry and laboratory medicine, 45(8): 953-61
Kamper-Jørgensen, M., Grønbaek, M., Tolstrup, J., Becker, U. (2004) Alcohol and cirrhosis: dose--response or threshold effect?. Journal of hepatology, 41(1): 25-30
Leevy, C.M., Moroianu, S.A. (2005) Nutritional aspects of alcoholic liver disease. Clinics in liver disease, 9(1): 67-81
Lefkowitch, J.H. (2005) Morphology of alcoholic liver disease. Clinics in liver disease, 9(1): 37-53
Levitsky, J., Mailliard, M.E. (2004) Diagnosis and therapy of alcoholic liver disease. Seminars in liver disease, 24(3): 233-47
Lieber, C.S. (2004) New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Current gastroenterology reports, 6(1): 60-5
Mandayam, S., Jamal, M., Morgan, T.R. (2004) Epidemiology of alcoholic liver disease. Seminars in liver disease, 24(3): 217-32
Mendez-Sanchez, N., Almeda-Valdes, P., Uribe, M. (2005) Alcoholic liver disease. An update. Ann Hepatol, 4(1); 32-42
Niemela, O. (2007) Biomarkers in alcoholism. Clinica Chimica Acta, 377(1-2): 39
Nyblom, H. (2004) High ast/alt ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol and Alcoholism, 39(4): 336-339
Pedersen, T.R., Faergeman, O., Kastelein, J.J.P., Olsson, A.G., Tikkanen, M.J., Holme, I., Larsen, M.L., Bendiksen, F.S., Lindahl, C., Palmer, G. (2004) Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. American Journal of Cardiology, 94(6): 720-724
Pessione, F., Ramond, M-J., Peters, L., Pham, B-N., Batel, P., Rueff, B., Valla, D-C. (2003) Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver International, 23(1): 45-53
Rosengren, A., Hawken, S., Ounpuu, S., Sliwa, K., Zubaid, M., Almahmeed, W.A., Blackett, K.N., Sitthi-Chitr,, Sato, H., Yusuf, S., INTERHEART investigators (2004) Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): Case-control study. Lancet, 364(9438): 953-62
Shiffman, R.N., Shekelle, P., Overhage, J.M., Slutsky, J., Grimshaw, J., Deshpande, A.M. (2003) Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med, 139(6); 493-8
Sougioultzis, S., Dalakas, E., Hayes, P.C., Plevris, J.N. (2005) Alcoholic hepatitis: from pathogenesis to treatment. Current medical research and opinion, 21(9): 1337-46
Trabut, J.-B., Plat, A., Thepot, V., Fontaine, H., Vallet-Pichard, A., Nalpas, B., Pol, S. (2008) Influence of Liver Biopsy on Abstinence in Alcohol-Dependent Patients. Alcohol and Alcoholism, 43(5): 559-563
Yoon, Y.H., Yi, H., Grant, B.F., i dr. (2002) Surveillance report 60: Liver cirrhosis mortality in the United States, 1970-99. Washington: National Institute on Alcohol Abuse and Alcoholism